US judge denies Sanofi-Aventis's bid to stop generic rival for Lovenox
This article was originally published in Scrip
Executive Summary
A federal judge has denied Sanofi-Aventis 's request fora preliminary injunction that would have directed the US FDA to suspend and withdraw its approval of a generic version of Lovenox (enoxaparin sodium) from Sandoz (Novartis) and partner Momenta Pharmaceuticals, which has been on the market for several weeks. As a result of the ruling, sales of generic Lovenox will proceed.